Qualigen Therapeutics, Inc. Stock price

Equities

QLGN

US74754R2022

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-27 pm EDT 5-day change 1st Jan Change
0.4 USD -0.25% Intraday chart for Qualigen Therapeutics, Inc. +10.86% -27.27%
Sales 2023 * 3.2M Sales 2024 * - Capitalization 2.07M
Net income 2023 * -13M Net income 2024 * -11M EV / Sales 2023 * 0.65 x
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 * -
P/E ratio 2023 *
-0.15 x
P/E ratio 2024 *
-0.4 x
Employees 35
Yield 2023 *
-
Yield 2024 *
-
Free-Float 88.73%
More Fundamentals * Assessed data
Dynamic Chart
Qualigen Therapeutics, Inc. announced that it expects to receive $0.55 million in funding from Alpha Capital Anstalt CI
Qualigen Therapeutics, Inc. Enters into A License and Sublicense Agreement with Pan-RAS Holdings, Inc CI
Qualigen Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Qualigen Therapeutics, Inc. Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors CI
Earnings Flash (QLGN) QUALIGEN THERAPEUTICS Reports Q2 Revenue $1.6M MT
Qualigen Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Qualigen Therapeutics Announces UD FDA IND Clearance to Initiate Phase 1 Clinical Trial of Qn-302 for Treatment of Advanced or Metastatic Solid Tumors CI
Chembio Diagnostics, Inc. acquired FastPack® diagnostics business from Qualigen Therapeutics, Inc. for $5.8 million. CI
Qualigen Therapeutics, Inc. Announces Resignation of Amy Broidrick as President, Chief Strategy and Operating Officer and Director CI
Poster Highlighting Qualigen Therapeutics’ Pan-RAS Inhibitor Platform Presented at American Society of Clinical Oncology 2023 Annual Meeting CI
Qualigen Therapeutics, Inc. Announces the Resignation of Amy Broidrick as President, Chief Strategy and Operating Officer and A Director, Effective June 16, 2023 CI
Earnings Flash (QLGN) QUALIGEN THERAPEUTICS Reports Q1 Revenue $1.6M MT
Qualigen Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Earnings Flash (QLGN) QUALIGEN THERAPEUTICS Posts Q4 Revenue $5M MT
Qualigen Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
More news
1 day-0.25%
1 week+10.86%
Current month-13.06%
1 month-18.40%
3 months-28.52%
6 months-61.17%
Current year-27.27%
More quotes
1 week
0.37
Extreme 0.3655
0.43
1 month
0.34
Extreme 0.337
0.48
Current year
0.34
Extreme 0.337
0.59
1 year
0.34
Extreme 0.337
1.26
3 years
0.34
Extreme 0.337
31.20
5 years
0.34
Extreme 0.337
75.00
10 years
0.34
Extreme 0.337
75.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 68 19-12-31
Director of Finance/CFO 59 01-12-31
Members of the board TitleAgeSince
Director/Board Member 68 19-12-31
Director/Board Member 74 20-12-06
Chief Executive Officer 68 19-12-31
More insiders
Date Price Change Volume
24-03-27 0.4 -0.25% 85,622
24-03-26 0.401 +4.16% 318,739
24-03-25 0.385 -1.03% 58,075
24-03-22 0.389 +5.76% 23,850
24-03-21 0.3678 +1.94% 86,003

Delayed Quote Nasdaq, March 27, 2024 at 04:30 pm EDT

More quotes
Qualigen Therapeutics, Inc. is a diversified life sciences company. The Company is focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug designation, while also commercializing diagnostics. Its cancer therapeutics pipeline includes QN-302, RAS and QN-247. QN-302 is a small molecule genomic quadruplex (G4) selective transcription inhibitor with a strong binding affinity to G4s prevalent in cancer cells. RAS is a family of rat sarcoma virus (RAS) oncogene protein-protein interaction inhibitor small molecules for preventing mutated RAS genes’ proteins from binding to their effector proteins; preventing this binding could stop tumor growth, especially in RAS-driven tumors such as pancreatic, colorectal and lung cancers. QN-247 is a deoxyribonucleic acid (DNA) coated gold nanoparticle cancer drug candidate that has the potential to target various types of cancer, including triple negative breast cancer, acute myeloid leukemia (AML) and glioblastoma.
More about the company
  1. Stock
  2. Equities
  3. Stock Qualigen Therapeutics, Inc. - Nasdaq